A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
Michael E Weinblatt, Clifton O Bingham 3rd, Gerd-Rüdiger Burmester, Vivian P Bykerk, Daniel E Furst, Xavier Mariette, Désirée van der Heijde, Ronald van Vollenhoven, Brenda VanLunen, Cécile Ecoffet, Christopher Cioffi, Paul Emery, Michael E Weinblatt, Clifton O Bingham 3rd, Gerd-Rüdiger Burmester, Vivian P Bykerk, Daniel E Furst, Xavier Mariette, Désirée van der Heijde, Ronald van Vollenhoven, Brenda VanLunen, Cécile Ecoffet, Christopher Cioffi, Paul Emery
Abstract
Objective: In disease-modifying antirheumatic drug-naive patients with early rheumatoid arthritis (RA) who had achieved sustained low disease activity (a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate of ≤3.2 at both week 40 and week 52) after 1 year of treatment with certolizumab pegol (CZP) at a standard dose (200 mg every 2 weeks plus optimized methotrexate [MTX]), we evaluated whether continuation of CZP treatment at a standard dose or at a reduced frequency (200 mg every 4 weeks plus MTX) was superior to stopping CZP (placebo plus MTX) in maintaining low disease activity for 1 additional year.
Methods: A total of 293 patients from period 1 of our study were re-randomized 2:3:2 in period 2 to CZP at a standard dose (n = 84), CZP at a reduced frequency (n = 127), or placebo plus MTX (CZP stopped) (n = 82). The primary end point was the percentage of patients who maintained low disease activity throughout weeks 52-104 without flares. We used a hierarchical testing scheme, comparing CZP at a standard dose with CZP stopped. If P < 0.05 was achieved, then CZP at a reduced frequency was compared with CZP stopped (nonresponder imputation).
Results: The 293 patients from period 1 represented 36% fewer patients than projected, yielding a smaller number of patients eligible for period 2. Higher proportions of patients treated with the standard and reduced frequency regimens maintained low disease activity than those who had stopped CZP (48.8% and 53.2%, respectively, versus 39.2% [P = 0.112 and P = 0.041, respectively; nominal P value, first hierarchical test not significant]). Similar trends were observed for radiographic nonprogression (change from baseline of ≤0.5 in modified Sharp/van der Heijde score; 79.2% and 77.9% of patients, respectively, versus 70.3%) and normative physical function (Health Assessment Questionnaire disability index score of ≤0.5; 71.4% and 70.6% of patients, respectively, versus 57.0%). Safety profiles were similar between all groups, with no new safety signals identified for continuing CZP to week 104. No deaths were reported.
Conclusion: The study failed to meet its primary end point. However, there were no clinically meaningful differences between the standard and reduced frequency doses of CZP plus MTX; both controlled RA more effectively than stopping CZP.
Trial registration: ClinicalTrials.gov NCT01521923.
© 2017 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology.
Figures
References
- Emamikia S, Arkema EV, Gyori N, Detert J, Chatzidionysiou K, Dougados M, et al. Induction maintenance with tumour necrosis factor‐inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta‐analysis of efficacy in randomised controlled trials. RMD Open 2016;2:e000323.
- Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1–25.
- Van Vollenhoven RF, Nagy G, Tak PP. Early start and stop of biologics: has the time come? BMC Med 2014;12:25.
- Nagy G, van Vollenhoven RF. Sustained biologic‐free and drug‐free remission in rheumatoid arthritis, where are we now? Arthritis Res Ther 2015;17:181.
- Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky DS, Naredo E, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 2016;75:1428–37.
- Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960–77.
- Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, et al. The first double‐blind, randomised, parallel‐group certolizumab pegol study in methotrexate‐naive early rheumatoid arthritis patients with poor prognostic factors, C‐OPERA, shows inhibition of radiographic progression. Ann Rheum Dis 2016;75:75–83.
- Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797–804.
- Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, et al. Certolizumab pegol in combination with dose‐optimised methotrexate in DMARD‐naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1‐year results from C‐EARLY, a randomised, double‐blind, placebo‐controlled phase III study. Ann Rheum Dis 2017;76:96–104.
- Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty‐eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
- Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.
- Van der Heijde DM, van Riel PL, Gribnau FW, Nuver‐Zwart IH, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036–8.
- Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin‐Mola E, Buch MH, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 2014;371:1781–92.
- Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383:321–32.
- Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573–86.
- Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A Simplified Disease Activity Index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244–57.
- Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, et al. Clinical benefit of 1‐year certolizumab pegol (CZP) add‐on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2‐year results of the C‐OPERA study, a phase III randomised trial. Ann Rheum Dis 2017;76:1348–56.
- Detert J, Bastian H, Listing J, Weiss A, Wassenberg S, Liebhaber A, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD‐naive patients with early rheumatoid arthritis: HIT HARD, an investigator‐initiated study. Ann Rheum Dis 2013;72:844–50.
- Emery P, Bingham CO, Bykerk VP, Furst DE, Mariette X, Purcaru O, et al. Improvements in patient‐reported outcomes and workplace and household productivity following 52 weeks of treatment with certolizumab pegol in combination with methotrexate in DMARD‐naïve early rheumatoid arthritis patients: results from the C‐EARLY randomized, double‐blind, controlled phase 3 study. Ann Rheum Dis 2015;74 Suppl 2:712.
- Bingham CO, Emery P, Weinblatt M, Burmester GR, Furst DE, Mariette X, et al. Maintenance of improvements in workplace and household productivity and physical function at 2 years in early RA patients with severe progressive disease who achieved sustained low disease activity following 1 year of initial therapy, with two dosing frequencies of certolizumab pegol. Ann Rheum Dis 2016;75 Suppl 2:226.
- Bijlsma JW, Welsing PM, Woodworth TG, Middelink LM, Petho‐Schramm A, Bernasconi C, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U‐Act‐Early): a multicentre, randomised, double‐blind, double‐dummy, strategy trial. Lancet 2016;388:343–55.
Source: PubMed